Member Info for yeboha

I dont think so , i hardly post on here, you on the other hand constant !

Wyn is a sad human who has nothing better to do but come on here and post !

I think avacta are playing it perfectly , think about it, they have said they want to keep the lead asset in house , so when they license out the other parts for funding which they will, as they move further on with the lead asset BP will start to panic !

Rorkersdrift : whos to say BP havent made an offer and Avacta have said its not enough , that really could be the case !

Also i like the value curve comment !

Just watched the interview and i thought it was another great one, that 59 year old that showed tumor shrinkage could of had lots more doses so thats huge, also he used the word unequivocally works again, what more do you need !

Im expecting news on a licencing deal very soon that's why, and at these prices its a gift !

Ive just bought a large chunk again, cant help myself at these ridiculously low prices ! I have a feeling Monday will be a rather good day indeed !

GOBBLE GOBBLE GOBBLE !

Yep taking advantage of the weak !

Gje306 : but yet they did have good news that wasnt expected , so that says alot doesn't it ! what will it do when given to people at the start of their treatment really is going to be transformative !

Who ??

We have learned in the last few weeks that :

Unequivocally it works

There has been Tumor shrinkage

They are planning on keeping the lead asset

Licensing deals Incoming

And i dont no if you heard Dr. Coughlin, she said there is even better to come !

These are all facts !

Yesterday, the company confirmed that the pre | CISION delivery platform works perfectly.

It can now be attached to hundreds of small molecules (and biologics) to dramatically improve their safety profile.

Pre | CISION goes head to head with the ADC market now. Cheaper, easier to manufacture, faster to develop.

“Which is more targeted?” depends on a head to head trial with a marketed ADC - which means sticking pre | CISION onto a warhead of a marketed ADC.

Seagen’s MMAE patent expires in 2025. Personal view is that

@avacta

is already working on the pre | CISION / MMAE molecule (remember, clinical work can be carried out on a molecule that includes MMAE; product just can’t be commercialised until patent expires). That would mean AVCT can launch a phase 1 trial immediately in early 2026.

That, or license / JV another (patented) ADC warhead to modify with pre | CISION and get into a head to head trial with an ADC, ASAP!

Vertizea : having Dr Tap on board is the one ! Like having it rubber stamped in gold !

Yesterday we learned it unequivocally works better than they even thought, and people sell , it just cracks me up, but hey ho , alot more cheap shares for me !

Couldn't be much clearer , i dont know what goes through people's heads i really dont !

AS said quote : unequivocally : in a way that is total, or expressed very clearly with no doubt

Yorkshire thats the thing a takeover or huge licensing deal could literally come at any point and i for one dont want to miss out on that to make a few extra share or a few pounds !

Again strangy, its a very educated guess , with all that has been said !